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Introduction
　Tocilizumab is a new biologic disease-modifying anti-
rheumatic drug directed against the activity of interleukin-6 
(IL-6), a key proinflammatory cytokine in the pathogenesis 
of rheumatoid arthritis (RA).1 This drug has proved highly 
effective in RA patients, including those who had previously 
not responded to anti-tumor necrosis factor (TNF) agents. 
However, because this drug reduces inflammation and less-
ens symptoms during IL-6 blocking activity, it should be 
noted that the rare but severe side effect of gastrointestinal 
perforations can occur.2
　We herein report a case of acute appendicitis that occurred 
during treatment of a RA patient with tocilizumab.
Case report
　A 55-year-old Japanese woman had a history of RA that 
had been diagnosed approximately 13 years prior to her ap-
pendicitis. She had been treated with steroids, methotrexate, 
and infliximab 5 months prior to the diagnosis of appendici-
tis, but had stopped the steroids. RA activity had then in-
creased at 4 months prior to the appendicitis, and tocilizum-
ab had been administered 1 month prior to the appendicitis. 
The patient had been experiencing abdominal distension and 
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diarrhea over a 3-day period, and she had visited the hospital 
to obtain a second dose of tocilizumab. No significant in-
flammatory changes were noted in laboratory tests, but ab-
dominal computed tomography (CT) revealed swelling of 
the appendix and the presence of ascites around the appen-
dix (Fig. 1). The patient was then referred to our hospital 
with a diagnosis of acute appendicitis. At the time of admis-
sion, her blood pressure was 154/98 mmHg with a heart rate 
of 112 beats/min, a body temperature of 37.2ºC, and an oxy-
gen saturation (SpO2) level of 99% on room air. Physical 
examination revealed mild tenderness in the right lower 
quadrant, without rebound tenderness. Laboratory tests re-
vealed a white blood cell (WBC) count of 11,100 cells/m3, a 
hemoglobin level of 15.2 g/dl, a platelet level of 10.8×104 
cells/m3, an albumin level of 4.1 g/dl, a blood urea nitrogen 
(BUN) level of 11.8 mg/dl, a creatinine level of 0.61 mg/dl, 
and a C-reactive protein (CRP) level of 0.35 mg/dl. The pa-
tientʼs transaminase level was normal. Although the acute 
appendicitis had appeared mild in the physical findings and 
laboratory data, we decided to conduct emergency surgery 
because CT revealed swelling of the appendix and the pres-
ence of ascites around the appendix and our sense was that 
the physical findings and laboratory data were not depend-
able due to the effect of the tocilizumab.
　The patient underwent operation under general anesthe-
sia, and a 5-cm Lennanderʼs pararectal incision was made. At 
the time of surgery, a perforated inflamed appendix and ab-
scess formation around the appendix were confirmed (Fig. 
2). Appendectomy was performed, the local area was irri-
gated with 3,000 ml of saline, and a drain was inserted into 
the pouch of Douglas. Pathological examination revealed 
the appendix with abscess formation and perforation (Fig. 
3). There were no effects of tocilizumab such as inhibition of 
inflammatory cell infiltration. The patient had an uneventful 
postoperative recovery, but we followed up carefully, taking 
the effects of the tocilizumab into consideration. On the first 
day after the operation, the patientʼs WBC count was 10,400 
cells/m3, and her CRP level was 0.55 mg/dl, and she began 
to take meals. On the third day after surgery, her WBC count 
had decreased to 8,100 cells/m3, her CRP level was 1.69 mg/
dl and her temperature was below 37.0ºC. On the fourth 
postoperative day, the drain was removed. On the fifth day, 
her WBC count had decreased to 6,700 cells/m3 and her CRP 
level was 1.33 mg/dl; antibiotics were stopped. However, on 
the seventh day, the patientʼs body temperature began to rise, 
and her RA symptoms steadily worsened. She was trans-
ferred to a hospital specializing in RA on the fourteenth day 
after surgery. The previous administration of tocilizumab did 
not appear to have affected the healing process.
Figure 2. Surgical findings. A perforated inflamed appendix and 
abscess formation around the appendix were confirmed (arrow).
Figure 3. Pathological examination revealed the appendix with 
abscess fomation and perforation (arrow). There were no effects 
of tocilizumab such as inhibition of inflammatory cell infiltration.
Figure 1. CT images. Abdominal CT revealed a swelling of the 
appendix and the presence of ascites around the appendix (arrow).
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　The anti-inflammatory effects of tocilizumab may mask 
signs of infection and typical symptoms such as the Blum-
berg sign in acute appendicitis. Furthermore, serum CRP 
concentrations do not increase during tocilizumab therapy.3,4 
Therefore, physicians must be aware that severe infections 
may be hidden in the conditions inferred from the clinical 
findings of a patient under tocilizumab treatment. 
　Clinical trials and the above-mentioned combined analy-
sis showed a rate of gastrointestinal perforation following 
tocilizumab treatment of 0.26 per100 patient years.5 Accord-
ing to a post-marketing study of tocilizumab for RA in Ja-
pan, 7 gastrointestinal perforations were reported in 6 pa-
tients.6 During Roche clinical trials abroad, 26 cases (0.65%) 
of gastrointestinal perforation were found among RA pa-
tients treated with tocilizumab at a rate of 1.9 per 1,000 pa-
tient years, of which most cases appeared to be complica-
tions of diverticulitis.7 There is consensus that tocilizumab 
should not be used in patients with a history of gastrointesti-
nal perforation, intestinal ulcers or diverticulitis. According 
to Nakahara et al.8, anti-IL-6R mAb therapy reduces vascu-
lar endothelial growth factor (VEGF) in RA. Thus, this may 
be the mechanism by which tocilizumab causes gastrointes-
tinal perforation, and we plan to continue research on this 
question. 
　Corticosteroids also mask many of the inflammatory signs 
of bowel perforation. Because the typical clinical sign of 
peritonitis is often absent, the interval between onset of 
symptoms and diagnosis of perforation is delayed.9,10 
　Tocilizumab is a new drug for RA therapy, and is therefore 
relatively unfamiliar to most surgeons in comparison with 
corticosteroids. It should be widely noted that the adminis-
tration of tocilizumab masks physical symptoms in acute 
abdomen patients and laboratory data may be misleading. 
Therefore, surgeons must take particular care in determining 
the most appropriate timing of surgical intervention.
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